AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Real-world, Multi-center, Prospective, Observational Study for PNH in China
Active, not recruiting
- Conditions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 724
- Registration Number
- NCT06154512
- Locations
- π¨π³
Research Site, Hangzhou, China
A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 88
- Registration Number
- NCT06151964
- Locations
- πΈπͺ
Research Site, Uppsala, Sweden
A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4000
- Registration Number
- NCT06147830
- Locations
- π¬π§
Research Site, Southampton, United Kingdom
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 243
- Registration Number
- NCT06147063
- Locations
- πΊπΈ
Research Site, North Charleston, South Carolina, United States
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 118
- Registration Number
- NCT06138795
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06137118
- Locations
- π¬π§
Research Site, Surrey, United Kingdom
Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 66
- Registration Number
- NCT06139991
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT06137144
- Locations
- π¬π§
Research Site, Oxford, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 76
- Registration Number
- NCT06132841
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients
Recruiting
- Conditions
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2700
- Registration Number
- NCT06131424
- Locations
- π»π³
Research Site, Hue, Vietnam
Β© Copyright 2024. All Rights Reserved by MedPath